#1 Clinical Trials Search in Europe

F770/05

A groundbreaking clinical trial is underway to assess the safety and effectiveness of TP-102, a new topical treatment for diabetic foot infections. This innovative therapy uses a combination of bacteriophages, which are viruses that target specific bacteria, to combat infections caused by common pathogens in diabetic foot ulcers. The study aims to explore how TP-102 performs compared to standard care, potentially offering a new approach to managing this challenging condition.

Table of Contents

What is F770/05?

F770/05 is one of the five components in a new medication called TP-102. This medication is currently being studied for its potential to treat diabetic foot infections. F770/05 is classified as a bacteriophage, which is a type of virus that specifically targets and destroys bacteria.[1]

TP-102 Bacteriophage Therapy

TP-102 is a bacteriophage cocktail that contains five different bacteriophages, including F770/05. The other components are F44/10, F125/10, F510/08, and F1245/05. This combination is designed to target specific bacteria that commonly cause infections in diabetic foot ulcers.[1]

Bacteriophage therapy is an innovative approach to treating bacterial infections. Instead of using traditional antibiotics, it uses viruses (bacteriophages) that are harmless to humans but can kill specific bacteria.

Target Conditions

TP-102, which includes F770/05, is being developed to treat diabetic foot ulcers infected by specific bacteria. The target bacteria are:

  • Acinetobacter baumannii
  • Pseudomonas aeruginosa
  • Staphylococcus aureus

These bacteria are common causes of infections in people with diabetic foot ulcers, which can be difficult to treat with conventional antibiotics.[1]

Clinical Trial Details

F770/05, as part of TP-102, is currently being studied in a Phase 2b clinical trial. This trial aims to evaluate the safety and effectiveness of TP-102 when applied topically (on the skin) to treat diabetic foot infections.[1]

The main objectives of this study are:

  1. To assess the safety and tolerability of TP-102 compared to a placebo, in addition to standard care
  2. To evaluate the clinical improvement in diabetic foot infection classification
  3. To examine the effects of TP-102 on wound healing

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some key eligibility requirements include:[1]

  • Being 18 years or older
  • Having a diagnosis of Type I or Type II diabetes
  • Having a diabetic foot infection that meets specific criteria, such as being present for at least 3 weeks and having a wound area of 20 cm² or less
  • Having an infection caused by at least one of the target bacteria (Pseudomonas aeruginosa, Staphylococcus aureus, or Acinetobacter baumannii)

There are also several exclusion criteria, such as pregnancy, breastfeeding, or having certain medical conditions that might interfere with the study.

Treatment Administration

TP-102, which contains F770/05, is administered as a topical suspension. This means it’s applied directly to the infected wound on the foot. The treatment is given in addition to standard care for diabetic foot infections.[1]

Expected Outcomes

The researchers are looking at several outcomes to determine if TP-102 (including F770/05) is effective. These include:[1]

  • Reduction in wound surface area
  • Improvement in infection classification
  • Changes in wound healing markers
  • Eradication of the target bacteria

They will compare these outcomes between patients receiving TP-102 and those receiving a placebo, both in addition to standard care.

Safety Considerations

As with any new treatment, safety is a primary concern. The study will closely monitor for any side effects or adverse events related to the use of TP-102. Patients with hypersensitivity to any component of the investigational product are not eligible to participate in the study.[1]

It’s important to note that while F770/05 and TP-102 show promise, they are still experimental treatments. More research is needed to fully understand their effectiveness and safety in treating diabetic foot infections.

Aspect Details
Study Type Phase 2b Clinical Study
Treatment TP-102 (bacteriophage therapy)
Administration Topical application on wound
Target Condition Diabetic foot ulcers infected by specific bacteria
Primary Objectives Safety, tolerability, clinical improvement, wound healing
Key Inclusion Criteria Adults with diabetes, specific foot infection characteristics
Treatment Duration Up to 31 days
Primary Endpoints Adverse events, infection classification changes, wound size reduction

FAQ

  • What is TP-102 and how does it work? TP-102 is a topical bacteriophage therapy consisting of five different bacteriophages (F44/10, F125/10, F770/05, F510/08, F1245/05). Bacteriophages are viruses that specifically target and destroy bacteria. In this case, TP-102 is designed to combat infections caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus in diabetic foot ulcers.
  • Who can participate in this clinical trial? The trial is open to adults (18 years or older) with diabetes who have a foot infection that has been present for at least 3 weeks. The infection must be classified as mild to moderate and caused by specific bacteria that TP-102 can target. Participants must also meet other health criteria, including having a glycosylated hemoglobin (HbA1c) value of 12.0% or less.
  • What are the main goals of this study? The primary objectives of the study are to evaluate the safety and tolerability of TP-102 compared to a placebo, assess its effectiveness in improving diabetic foot infection classification, and measure its impact on wound healing. The study also aims to examine changes in infection-related blood markers and the eradication of targeted bacterial strains.
  • How is the treatment administered? TP-102 is applied topically to the wound. The maximum daily dose is 1 unit (the exact measurement is not specified), and the maximum treatment period is 31 days.
  • What potential benefits could this therapy offer? If successful, TP-102 could provide a new treatment option for diabetic foot infections that is more targeted and potentially more effective than current standard care. It may help improve wound healing, reduce infection severity, and eradicate harmful bacteria without the use of traditional antibiotics.

Ongoing Clinical Trials on F770/05

  • Study on the Safety and Effectiveness of TP-102 for Treating Diabetic Foot Infections in Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

Glossary

  • Bacteriophage: A type of virus that specifically infects and destroys bacteria. In this study, bacteriophages are being used as a targeted therapy against specific bacterial infections in diabetic foot ulcers.
  • Diabetic Foot Infection: An infection that occurs in a foot wound of a person with diabetes. These infections can be serious due to the compromised healing ability in diabetic patients.
  • IWGDF/IDSA Classification: A system used to categorize the severity of diabetic foot infections, ranging from mild to severe. This helps healthcare providers determine appropriate treatment.
  • Topical Administration: Application of a medication directly to the skin or wound, as opposed to taking it orally or through injection.
  • Standard of Care (SoC): The currently accepted treatment methods for a particular condition. In this study, TP-102 is being tested in addition to the standard care for diabetic foot infections.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs. In this study, some participants will receive a placebo instead of TP-102 to compare outcomes.
  • Glycosylated Hemoglobin (HbA1c): A blood test that measures average blood sugar levels over the past 2-3 months. It's used to diagnose and monitor diabetes.
  • PEDIS Classification: A system used to assess diabetic foot ulcers based on Perfusion, Extent, Depth, Infection, and Sensation.
  • Treatment Emergent Adverse Events (TEAEs): Any unfavorable and unintended sign, symptom, or disease that appears or worsens after starting a medical treatment.
  • End of Treatment (EOT): The point at which a participant completes the full course of treatment in a clinical trial.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tp-102-for-treating-diabetic-foot-infections-in-patients/